These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

771 related articles for article (PubMed ID: 32004485)

  • 41. A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation.
    Gaballa S; Palmisiano N; Alpdogan O; Carabasi M; Filicko-O'Hara J; Kasner M; Kraft WK; Leiby B; Martinez-Outschoorn U; O'Hara W; Pro B; Rudolph S; Sharma M; Wagner JL; Weiss M; Flomenberg N; Grosso D
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):141-8. PubMed ID: 26415558
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 44. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
    Mengarelli A; Iori AP; Romano A; Cerretti R; Cerilli L; De Propris MS; Fenu S; Moleti ML; De Felice L; Girelli G; Arcese W
    Haematologica; 2003 Mar; 88(3):315-23. PubMed ID: 12651271
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
    Pérez-Simón JA; Martino R; Caballero D; Valcarcel D; Rebollo N; de la Cámara R; de Oteiza JP; Heras I; Calvo MV; Sierra J; San Miguel JF;
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):664-71. PubMed ID: 18489992
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies.
    Jacoby E; Chen A; Loeb DM; Gamper CJ; Zambidis E; Llosa NJ; Huo J; Cooke KR; Jones R; Fuchs E; Luznik L; Symons HJ
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):112-8. PubMed ID: 26343947
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
    Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L
    Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
    Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
    Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation.
    Ciurea SO; Al Malki MM; Kongtim P; Fuchs EJ; Luznik L; Huang XJ; Ciceri F; Locatelli F; Aversa F; Castagna L; Bacigalupo A; Martelli M; Blaise D; Ben Soussan P; Arnault Y; Handgretinger R; Roy DC; O'Donnell PV; Bashey A; Solomon S; Romee R; Gayoso J; Lazarus HM; Ballen K; Savani BN; Mohty M; Nagler A
    Bone Marrow Transplant; 2020 Jan; 55(1):12-24. PubMed ID: 30833742
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Similar outcomes of peripheral blood stem cells vs. bone marrow for human leukocyte antigen-matched unrelated donor transplantation in adult patients with acute myeloid leukemia using risk-adapted graft-versus-host disease prophylaxis.
    Shin SH; Kim JH; Jeon YW; Yoon JH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
    Eur J Haematol; 2014 Jul; 93(1):19-28. PubMed ID: 24527665
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
    Alousi AM; Brammer JE; Saliba RM; Andersson B; Popat U; Hosing C; Jones R; Shpall EJ; Khouri I; Qazilbash M; Nieto Y; Shah N; Ahmed S; Oran B; Al Atrash G; Ciurea S; Kebriaei P; Chen J; Rondon G; Champlin RE
    Biol Blood Marrow Transplant; 2015 May; 21(5):906-12. PubMed ID: 25667989
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.
    Lazarus HM; Koc ON; Devine SM; Curtin P; Maziarz RT; Holland HK; Shpall EJ; McCarthy P; Atkinson K; Cooper BW; Gerson SL; Laughlin MJ; Loberiza FR; Moseley AB; Bacigalupo A
    Biol Blood Marrow Transplant; 2005 May; 11(5):389-98. PubMed ID: 15846293
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Single-agent GvHD prophylaxis with tacrolimus after post-transplant high-dose cyclophosphamide is a valid option for haploidentical transplantation in adults with hematological malignancies.
    Esquirol A; Pascual MJ; Ortiz M; Piñana JL; Ferra C; Garcia Cadenas I; Vilades I; Brunet S; Martino R; Sierra J
    Bone Marrow Transplant; 2017 Sep; 52(9):1273-1279. PubMed ID: 28604667
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
    Cutler C; Kim HT; Hochberg E; Ho V; Alyea E; Lee SJ; Fisher DC; Miklos D; Levin J; Sonis S; Soiffer RJ; Antin JH
    Biol Blood Marrow Transplant; 2004 May; 10(5):328-36. PubMed ID: 15111932
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation.
    Massenkeil G; Rackwitz S; Genvresse I; Rosen O; Dörken B; Arnold R
    Bone Marrow Transplant; 2002 Dec; 30(12):899-903. PubMed ID: 12476283
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation.
    Dey BR; McAfee S; Colby C; Sackstein R; Saidman S; Tarbell N; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2003 May; 9(5):320-9. PubMed ID: 12766882
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
    Schwinghammer TL; Bloom EJ
    Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Rubio MT; Labopin M; Blaise D; Socié G; Contreras RR; Chevallier P; Sanz MA; Vigouroux S; Huynh A; Shimoni A; Bulabois CE; Caminos N; López-Corral L; Nagler A; Mohty M
    Haematologica; 2015 May; 100(5):683-9. PubMed ID: 25769546
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant.
    Ruggeri A; Sun Y; Labopin M; Bacigalupo A; Lorentino F; Arcese W; Santarone S; Gülbas Z; Blaise D; Messina G; Ghavamzadeh A; Malard F; Bruno B; Diez-Martin JL; Koc Y; Ciceri F; Mohty M; Nagler A
    Haematologica; 2017 Feb; 102(2):401-410. PubMed ID: 27758821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.